Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.96 USD | -4.21% | -1.85% | +186.85% |
Financials (USD)
Sales 2024 * | 15M | Sales 2025 * | 16.99M | Capitalization | 2.48B |
---|---|---|---|---|---|
Net income 2024 * | -284M | Net income 2025 * | -326M | EV / Sales 2024 * | 165 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 146 x |
P/E ratio 2024 * |
-8.11
x | P/E ratio 2025 * |
-7.74
x | Employees | 253 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.27% |
Latest transcript on Avidity Biosciences, Inc.
1 day | -4.21% | ||
1 week | -1.85% | ||
Current month | +7.58% | ||
1 month | +2.41% | ||
3 months | +94.46% | ||
6 months | +373.72% | ||
Current year | +186.85% |
Managers | Title | Age | Since |
---|---|---|---|
Troy Wilson
FOU | Founder | 55 | 12-11-12 |
Sarah Boyce
CEO | Chief Executive Officer | 52 | 19-09-30 |
Michael MacLean
DFI | Director of Finance/CFO | 58 | 20-05-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arthur Levin
BRD | Director/Board Member | 70 | 13-09-30 |
Carsten Boess
BRD | Director/Board Member | 57 | 20-04-12 |
Edward Kaye
BRD | Director/Board Member | 74 | 19-08-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.11% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - | |
0.08% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 25.96 | -4.21% | 1,162,942 |
24-05-09 | 27.1 | +3.99% | 1,235,116 |
24-05-08 | 26.06 | +2.64% | 804,094 |
24-05-07 | 25.39 | -3.57% | 682,086 |
24-05-06 | 26.33 | -0.45% | 693,907 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+186.85% | 2.48B | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- RNA Stock